β‐alanine supplementation in adults with overweight and obesity: a randomized controlled feasibility trial
Authors' conclusion
Sustained-release β-alanine supplementation is well tolerated and adhered to in adults with overweight and obesity. Future research should consider more advanced metabolic conditions, which may benefit from longer duration supplementation.
Study context
- Population
- Adults with overweight and obesity (44% female; mean age 58 years, BMI 31.1 kg/m², HbA1c 39.8 mmol/mol)
- Participants
- 27 adults
- Comparison
- β-alanine vs matched placebo for 3 months
- Primary endpoint
- Feasibility and tolerability: adherence, side effects, recruitment, attrition and blinding
- Follow-up
- 3 months
Methodological detailsfeasibility trial, placebo-controlled
- Feasibility trial
- Placebo-controlled
Primary result
As reported in the abstract
Adherence
Placebo
0.91
95% CrI 0.84–0.95
β-alanine
0.92
95% CrI 0.85–0.95
Further findings
Exploratory cardiometabolic, cardiovascular and clinical biochemical outcomes
- Probability that β-alanine affected cardiometabolic, cardiovascular or clinical biochemical outcomes was low
Safety
- Side effects remained at or below baseline throughout
Original publication
β‐alanine supplementation in adults with overweight and obesity: a randomized controlled feasibility trial. Obesity (Silver Spring). Published 12 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →